The Cigna Group (NYSE: CI) has drawn considerable attention from investors searching for the stock's next potential milestone. The $400 price target has gained prominence after UBS raised its objective to exactly that level in May 2026, calling CI its top pick in the Healthcare Facilities & Managed Care sector. With the stock trading near $292 in early July 2026, reaching $400 would require a move of roughly 37% — a significant but not unprecedented rally for a large-cap healthcare stock with Cigna's fundamental profile.
Cigna operates through two primary segments: Evernorth Health Services, which encompasses pharmacy benefits, specialty pharmacy, and care delivery solutions, and Cigna Healthcare, which provides medical insurance to approximately 16 million U.S. members and 2 million international members. The company's market capitalization stands at roughly $77 billion, placing it among the largest managed care organizations globally. Revenue reached approximately $262 billion in the most recent fiscal year, though analysts project a decline of roughly 6-7% in the coming year as the company navigates PBM contract renewals and pricing model transitions.
Despite top-line pressure, Cigna's profitability metrics remain robust. Return on equity (ROE) of approximately 16% and substantial free cash flow generation provide ample resources for the company's aggressive capital return program, which has included repurchasing over 133 million shares in a single quarter during 2025.
Several factors could propel Cigna shares toward the $400 target. First, the valuation argument is difficult to ignore. A forward P/E below 10 represents a historically cheap entry point, and any expansion toward even 12-13 times earnings — still modest by industry standards — would significantly lift the stock price. UBS has noted that Cigna's current valuation implies 2026 estimated earnings well below what the firm projects, suggesting meaningful upside if earnings simply meet consensus expectations.
Second, the specialty pharmacy business within Evernorth continues to expand. Cigna's $3.5 billion investment in Shields Health Solutions signals confidence in this high-growth vertical. As specialty drug spending increases across the healthcare system, Cigna's integrated PBM and specialty pharmacy infrastructure positions it to capture a growing share of this market.
Third, the company's buyback program mechanically boosts EPS by reducing the share count. When combined with Cigna's low dividend payout ratio of roughly 5%, the capital return runway appears long and sustainable.
The path to $400 is not without substantial obstacles. Cigna's PBM business — historically a reliable growth engine — faces increasing regulatory scrutiny and pricing pressure. The company's transition toward a rebate-free PBM model, while potentially more sustainable long-term, introduces near-term margin uncertainty. Bernstein analysts acknowledged the new model is "more sustainable" but cautioned they were "not expecting valuation rerating yet."
Stop-loss insurance, another important product line, has experienced elevated medical cost trends that pressured profitability in 2024 and early 2025. Although TD Cowen's employer survey suggests improvement, the segment remains a swing factor for quarterly results. Additionally, notable insider selling activity — with approximately $60 million in shares sold over a recent three-month period — warrants attention, even if insider transactions can occur for reasons unrelated to company outlook.
Perhaps most significantly, several analysts lowered their price targets in late 2025, with Goldman Sachs trimming its target to $330 and Barclays downgrading the stock to an Equal-Weight rating with a $304 target. This shift in sentiment reflects real concerns about the pace of earnings growth.
The overall analyst consensus remains bullish, with approximately 20 of 24 covering analysts maintaining Buy-equivalent ratings. The average 12-month price target sits near $341, implying roughly 17% upside from current levels. Targets range from approximately $290 at the low end to $400 at the high end. Notable bulls include Bank of America ($378 target), Bernstein ($371), Morgan Stanley ($361), and Mizuho ($340). On the more cautious side, Wells Fargo maintains a Hold rating with a $305 target, and Deutsche Bank moved to the sidelines with a $302 target.
The gap between the $341 consensus and the $400 high target underscores that reaching the upper boundary would require everything to go right — sustained earnings beats, successful PBM model execution, favorable medical cost trends, and multiple expansion.
From a technical perspective, CI faces several layers of potential resistance. The $300 level serves as both a psychological round number and a zone where the stock has struggled to hold above in recent months. Above that, the $315–$340 range represents a cluster of previous support and resistance from late 2025 trading, coinciding closely with the analyst consensus target zone. The $370–$378 area marks another significant hurdle, aligning with Bank of America's target and previous price peaks from earlier in 2025. Only after clearing these levels could a sustained push toward $400 become technically viable.
On the support side, the $280 area has provided a floor in recent weeks, with the $240–$245 zone representing the major support level established during the October 2025 selloff.
Traders seeking a data-driven edge in timing their entries and exits can turn to Tickeron's AI Daily Buy/Sell Signals, a tool that continuously monitors thousands of stocks and ETFs using artificial intelligence. The platform generates Buy, Sell, or Hold signals based on evolving market conditions, technical patterns, and AI-driven analysis, helping traders identify opportunities and manage existing positions more efficiently. For those following CI and other healthcare names, these signals offer a structured way to track shifting market sentiment without manually monitoring every chart and indicator.
The question of whether Cigna can reach $400 ultimately depends on time horizon and execution. In the near term, the $300–$340 range appears more realistic given current earnings trajectories and the absence of an obvious catalyst for multiple expansion. Over a multi-year period, however, the combination of a deeply discounted valuation, aggressive share repurchases, specialty pharmacy growth, and PBM model stabilization could create conditions where $400 becomes attainable. The strongest arguments in favor are the extremely low forward P/E and the mechanical EPS boost from buybacks. The primary risks — PBM uncertainty, revenue headwinds, and the possibility that the market never awards a higher multiple — mean that investors should monitor earnings execution, stop-loss medical cost trends, and any regulatory developments in the pharmacy benefit space before concluding that $400 is within reach.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, CI has been loosely correlated with CVS. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if CI jumps, then CVS could also see price increases.